Real-World Study Finds Oral Combination Therapy of Macitentan, Riociguat, and Selexipag Effective in PAH

March 02, 2021 10:45pm

Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH.

Irregular Sleep Schedule Linked With Depression, Worse Mood
Mixed Improvements Seen Among Patients With MS Practicing Mindfulness
Exercise Timing Linked to Cardiorespiratory Fitness in Men With T2D
FDA Approves First Treatment for Rare Genetic Metabolic Pediatric Disorder